CAT-248 / Catamaran Bio - LARVOL DELTA

CAT-248 (engineered NK cells expressing CD70 CAR, IL15, and TGFβ DNR) demonstrates in vivo expansion, tumor infiltration, and durable regression of multiple CD70-expressing xenograft tumors (SITC 2023) - "Conclusions CAT-248 infiltrates and durably regresses tumor xenografts expressing CD70 at high, medium or low antigen densities. CAT-248 has the potential to be a potent and durably effective allogeneic NK cell therapy for CD70 expressing solid tumors."

IO biomarker • Preclinical • Genito-urinary Cancer • Hematological Malignancies • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Renal Cell Carcinoma • Solid Tumor • CD70 • IL15 • TGFB1

Spinner Flask Modelling of Wave-Style Bioreactors Enables Suspension-Phase Cell Culture Process Development of Allogeneic CAR-NK Cell Therapies (ASGCT 2023) - "Two distinct CAR-NK products, CAT-179 and CAT-248, were produced in three different culture systems: 150mL spinner flasks, 1L static cultures and 2L wave-style bioreactors. Use of the model revealed that the optimization of this parameter is critical to maximizing the yield of potent drug products in the CAT-248 process.¶In summary, our data demonstrates proof of concept for the use of spinner flasks for culturing NK cells, providing a small-scale platform to model a wave-style suspension culture process more accurately. Use of this model will expedite scale-up process development as we pursue our clinical goals, shortening the path to clinical readiness and supplying a more complete data package in support of the clinical manufacturing of multiplex-engineered NK cells for solid tumor applications."

Preclinical • Hematological Disorders • Hematological Malignancies • Oncology • Solid Tumor

CAT-248, an allogeneic CD70-directed CAR-NK cell therapy effectively controls CD70-positive tumor xenografts (AACR 2023) - "Further, CAT-248 cells demonstrated significant in vivo persistence beyond 4 weeks post-dosing in peripheral blood. Overall, the results demonstrate the potential for CAT-248 as a novel off-the-shelf, cryopreserved, allogeneic NK cell therapy for CD70-positive renal cell carcinoma and other solid tumor malignancies."

Genito-urinary Cancer • Oncology • Renal Cell Carcinoma • Solid Tumor • CD70 • IFNG • IL15 • TGFB1 • TNFA

Catamaran Bio Announces Preclinical Data from Allogeneic CAR-NK Cell Therapy Pipeline for Solid Tumors to be Presented at the American Association for Cancer Research (AACR) Annual Meeting 2023 (GlobeNewswire) - "Catamaran Bio, Inc...announced new data demonstrating preclinical pharmacology and in vivo efficacy from the Company’s two CAR-NK cell therapies in solid tumors have been selected for poster presentations during the American Association for Cancer Research (AACR) Annual Meeting taking place April 14-19, 2023, at the Orange County Convention Center in Orlando, FL....'These advances are part of our continuing progress toward the clinic and lay the foundation for our first in-human studies in solid tumors to begin in 2024'....Demonstration that CAT-248 significantly reduces growth of 786-O renal cell carcinoma xenografts in both intraperitoneal and subcutaneous in vivo models....Demonstration that a single dose of TAILWIND^®-engineered CAR-NK cells induces durable regression in multiple HER2 xenograft models."

New trial • Preclinical • Genito-urinary Cancer • Kidney Cancer • Oncology • Renal Cell Carcinoma • Solid Tumor

Engineering CD70-Directed CAR-NK Cells for the Treatment of Hematological and Solid Malignancies (SITC 2022) - "In functional assays, CD70 knockout CAR-NK cells mediated cytotoxicity against multiple CD70-positive tumor cell lines including AML and RCC both in vitro and in vivo . Conclusions Overall, the results demonstrate the potential for targeting CD70 with CAR-NK cell therapy for the treatment of AML, RCC, and other CD70-positive malignancies while overcoming fratricide issues by engineering with a non-viral transposon delivery system in combination with CRISPR/Cas9 editing."

IO biomarker • Acute Myelogenous Leukemia • Genito-urinary Cancer • Hematological Malignancies • Leukemia • Oncology • Renal Cell Carcinoma • Solid Tumor • CD70 • IL15

Catamaran Bio Presents Preclinical Efficacy Data for Two Allogeneic CAR-NK Cell Therapies for Solid Tumors at SITC 2022 Annual Meeting (Businesswire) - "Catamaran Bio, Inc...announced new data demonstrating preclinical efficacy of two CAR-NK cell therapies in solid and hematological cancers....Data supporting Catamaran’s lead program, CAT-248, will be presented in a poster...Highlights include: The non-viral TcBuster™ Transposon System was used to deliver transposons containing a CD70 CAR or CD70 CAR/IL15 expression cassette in primary human peripheral blood NK (PBNK) cells; Knockout of CD70 via CRISPR/Cas9 in CD70 CAR-expressing NK cells mitigated fratricide and increased cell yield; Engineered cells were highly cytotoxic against multiple CD70-positive tumor cells lines derived from renal cell carcinoma (RCC) and acute myeloid leukemia (AML); A single dose of engineered NK cells expressing CD70 CAR and secreted IL15 reduced tumor burden and increased survival in an RCC xenograft model, without the need for exogenous IL15."

Preclinical • Acute Myelogenous Leukemia • Genito-urinary Cancer • Hematological Malignancies • Kidney Cancer • Leukemia • Oncology • Renal Cell Carcinoma • Solid Tumor

Catamaran Bio to Present Preclinical Efficacy Data for Allogeneic CAR‑NK Cell Therapies to Treat Solid Tumors at SITC Annual Meeting (Businesswire) - "Catamaran Bio, Inc...announced that the company will present preclinical efficacy data for its allogeneic, cryopreserved CAR-NK cell therapies designed to treat solid tumors, engineered using Catamaran’s TAILWIND^TM platform. The data demonstrate the promise of two of the company’s CAR-NK cell therapies, CAT-248 and CAT-179, for the treatment of solid tumors, and will be presented in two poster presentations at the Society for Immunotherapy in Cancer (SITC) 37th Annual Meeting, being held in Boston, Massachusetts, November 8-12, 2022."

Preclinical • Hematological Malignancies • Oncology • Solid Tumor

Catamaran Bio Expands Collaboration for CAR‑NK Cell Engineering with the University of Minnesota and Secures an Exclusive Patent License to Next Generation Manufacturing Technologies (Businesswire) - “Catamaran Bio, Inc…announced an expansion and extension of its research collaboration with Branden Moriarity, PhD, of the University of Minnesota, to further advance the versatility of transposon engineering for arming CAR-NK cell therapies with functional attributes not found in earlier generations of cell therapies. ‘This expanded collaboration and license demonstrate our commitment to develop and integrate the most advanced technologies for scalable and robust manufacturing of our allogeneic CAR-NK cell therapies’…In the new phase of the collaboration, research teams from the University of Minnesota and Catamaran will further optimize the TcBusterTM transposon system, a next generation nonviral genetic modification system which has been integrated into Catamaran’s TAILWINDTM platform. TcBuster was engineered for use in human immune cells…Catamaran licensed the TcBuster transposon system from Bio-Techne Corporation.”

Licensing / partnership • Oncology • Solid Tumor

Engineering CD70-Directed CAR-NK Cells for the Treatment of Hematological and Solid Malignancies (ASH 2021) - "2008, Clin Cancer Res. 14(23):7763-7772."

IO biomarker • Acute Lymphocytic Leukemia • Acute Myelogenous Leukemia • Genito-urinary Cancer • Hematological Disorders • Hematological Malignancies • Leukemia • Lymphoma • Multiple Myeloma • Non-Hodgkin’s Lymphoma • Oncology • Renal Cell Carcinoma • Solid Tumor • CD70 • IFNG • IL15 • LAMP1 • TNFA

Catamaran Bio Announces Lead CAR-NK Cell Therapy Programs and Upcoming Data Presentation at ASH 2021 (Businesswire) - "Catamaran’s CAR-NK programs include CAT-179 targeting HER2-expressing breast and gastric cancers, and CAT-248 targeting CD70-expressing cancers....Catamaran Bio...today announced that it has designated CAT-179, a HER2-targeted CAR-NK cell therapy, and CAT-248, a CD70-targeted CAR-NK cell therapy, as its first preclinical development programs. The company also announced that data supporting the CAT-248 program will be presented during a poster session at the 63rd Annual Meeting of the American Society of Hematology (ASH) which will be held virtually and in person in Atlanta from December 11-14, 2021."

Preclinical • Breast Cancer • Gastric Cancer • Gastrointestinal Cancer • Hematological Malignancies • Oncology • Solid Tumor